Výsledky vyhledávání - "Gail L. Torkildsen"

Efficacy and Safety of Single-dose OC-02 (Simpinicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease: The PEARL Phase II Randomized Trial

Autor: Gail L, Torkildsen, Guruprasad R, Pattar, Gary, Jerkins, Kristen, Striffler, Jeffrey, Nau

Publikováno v: Clinical Therapeutics. 44:1178-1186

Dry eye disease is a multifactorial disorder that affects the ocular surface, with symptoms including ocular irritation, impaired vision, and pain. Nicotinic acetylcholine receptor (nAChR) agonists are novel treatments for dry eye disease; this study

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f89f2f889e58b603271deb672d5e9b5
https://doi.org/10.1016/j.clinthera.2022.07.006

Zobrazit plný text záznamu

ONSET-1 Phase 2b Randomized Trial to Evaluate the Safety and Efficacy of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease

Autor: David Wirta, Gail L. Torkildsen, Blair Boehmer, David A. Hollander, Edward Bendert, Lijuan Zeng, Michael Ackermann, Jeffrey Nau

Publikováno v: Cornea. 41(10)

The purpose of this trial was to evaluate the safety and efficacy of OC-01 (varenicline solution), a nicotinic acetylcholine receptor agonist nasal spray, on signs and symptoms of dry eye disease.A phase 2b, multicenter, randomized, double-masked, ve

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18462f331b9186995a78b1acdd3c55a5
https://pubmed.ncbi.nlm.nih.gov/36107843

Zobrazit plný text záznamu

Prolonged Effectiveness of Bepotastine Besilate Ophthalmic Solution for the Treatment of Ocular Symptoms of Allergic Conjunctivitis

Autor: Jon I. Williams, Kathryn S. Kennedy, James A. Gow, Gail L. Torkildsen, Mark B. Abelson, Paul J. Gomes, Timothy R. McNamara, for the Bepotastine Besil

Publikováno v: Journal of Ocular Pharmacology and Therapeutics. 27:385-393

This clinical trial evaluated the safety and effectiveness of bepotastine besilate ophthalmic solutions 1.0% and 1.5% compared with placebo for the treatment of ocular itching and conjunctival hyperemia (redness) using the conjunctival allergen chall

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea58800cf5860c719cf106929bee9865
https://doi.org/10.1089/jop.2011.0005

Zobrazit plný text záznamu

Evaluation of clinical efficacy and safety of tobramycin/dexamethasone ophthalmic suspension 0.3%/0.05% compared to azithromycin ophthalmic solution 1% in the treatment of moderate to severe acute blepharitis/blepharoconjunctivitis

Autor: Bruce Silverstein, William M Hammonds, Paul Cockrum, Steven M Silverstein, E. J. Meier, Gail L Torkildsen

Publikováno v: Current Medical Research and Opinion. 27:171-178

To evaluate the clinical efficacy and safety of tobramycin/dexamethasone (TobraDex ST ; 'ST') ophthalmic suspension 0.3%/0.05% compared to azithromycin (Azasite) ophthalmic solution (1%) in the treatment of moderate to severe blepharitis/blepharoconj

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90ded7c0759cf537af877ee8b79a47e4
https://doi.org/10.1185/03007995.2010.539603

Zobrazit plný text záznamu

Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: A phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children

Autor: Mark B, Abelson, Gail L, Torkildsen, Jon I, Williams, James A, Gow, Paul J, Gomes, Timothy R, McNamara

Publikováno v: Clinical Therapeutics. 31:1908-1921

Bepotastine besilate is a highly selective histamine H(1)-receptor antagonist with antihistaminic, mast cell stabilizing, and anti-inflammatory activity. Based on a history of clinical effectiveness and tolerability of oral bepotastine besilate in th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe661cc73555fe8b581c4ae33fa2f183
https://doi.org/10.1016/j.clinthera.2009.09.001

Zobrazit plný text záznamu

Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study

Autor: John D, Sheppard, Gail L, Torkildsen, John D, Lonsdale, Francis A, D'Ambrosio, Eugene B, McLaurin, Richard A, Eiferman, Kathryn S, Kennedy, Charles P, Semba, Gerald P, Spindel

Publikováno v: Ophthalmology. 121(2)

To assess the efficacy and safety of lifitegrast ophthalmic solution 5.0% compared with placebo in subjects with dry eye disease.Prospective, randomized, double-masked, placebo-controlled, parallel arm, multicenter clinical trial.A total of 588 adult

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::2a52549b9fc10e0b5e00b6b5922bc792
https://pubmed.ncbi.nlm.nih.gov/24289915

Zobrazit plný text záznamu

Integrated phase III trials of bepotastine besilate ophthalmic solution 1.5% for ocular itching associated with allergic conjunctivitis

Autor: Edward J. Meier, Gail L. Torkildsen, James A. Gow, Timothy R. McNamara, Paul J. Gomes, Jon I. Williams, null for the Bepotastine Besilate Ophthalmic Solut

Publikováno v: Allergy and asthma proceedings. 33(3)

Allergic conjunctivitis is a clinical reaction to environmental allergens and is manifested by ocular itching caused by IgE-induced mast cell degranulation. Bepotastine besilate is a selective H(1)-antagonist with mast cell stabilizing properties. Th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fab4e0d3224342d18d1e814bae564e6a
https://pubmed.ncbi.nlm.nih.gov/22991696

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání